Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis

Hui Luo; Saisai Li; Menghuang Zhao; Bo Sheng; Haiyan Zhu; Xueqiong Zhu

doi:10.18632/oncotarget.15982

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis

Hui Luo, Saisai Li, Menghuang Zhao, Bo Sheng, Haiyan Zhu and Xueqiong Zhu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:36845-36856. https://doi.org/10.18632/oncotarget.15982

Metrics: PDF 2375 views | HTML 2888 views | ?

Abstract

Hui Luo1, Saisai Li1, Menghuang Zhao1, Bo Sheng1, Haiyan Zhu1 and Xueqiong Zhu1

1 Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Correspondence to:

Xueqiong Zhu, email:

Haiyan Zhu, email:

Keywords: prognostic, progesterone receptor, ovarian cancer, meta-analysis

Received: December 16, 2016 Accepted: February 28, 2017 Published: March 07, 2017

Abstract

Objective: While a prognosis value of progesterone receptor (PR) in ovarian cancer has been reported in some publications, controversial data were presented by different reports. In order to address the disagreement of progesterone receptor in ovarian cancer survival, we conducted this meta-analysis.

Methods: Relevant articles on progesterone receptor and ovarian cancer prognosis were identified via a thorough search of PubMed, Embase and Cochrane Central. Hazard ratios (HR) and 95% confidence interval (CI) were extracted from studies on overall survival (OS) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS).

Result: A total of 28 eligible studies containing 5685 patients were collected for analysis. It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% CI = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS) (HR = 0.75, 95% CI = 0.61 to 0.93, P = 0.008) of ovarian cancer patients. Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method.

Conclusion: Progesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15982

Publication Alerts

Reviews:

Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis

Abstract